Toll like receptor 7 agonists for cancer immunotherapy

Bookmark and Share
Published: 25 Mar 2014
Views: 5607
Rating:
Save
Prof Stefan Endres - Ludwig-Maximilians-Universität, Munich, Germany

Dr Endres talks to ecancertv at the 1st Immunotherapy of Cancer Conference ( ITOC ) in Munich about toll like receptor 7 agonists for cancer immunotherapy

Toll like receptor 7 (TLR7) is from a class of proteins that play a key role in the innate immune system.

One approach is to combine TLR7 RNA with a chemical from the triphosphate group, inducing interferon and alpha helping the immune system to fight tumour cells.

Dr Endres covers the different approaches for activating the patient's own immune system to fight cancer.